Evaluation of PTEN, PI3K MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma

Wspolczesna Onkologia

Volumn 18, Issue 4, 2014, Pages 234-240

  Duman, Berna B ^a   Kara, Oʇuz I ^a   Uʇuz, Aysum ^a   Ates, Berna T ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

K Ras; MTOR; PI3K; PTEN; Thyroid cancer

Indexed keywords

K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P85;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE; SURVIVAL TIME;

EID: 84907208162     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.43803     Document Type: Article

References (41)

1. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010; 20: 697-706.
2. Mian C, Barollo S, Pennelli G, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) 2008; 68: 108-16.
3. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
4. Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 2010; 321: 20-8.
5. Legakis I, Syrigos K. Recent advances in molecular diagnosis of thyroid cancer. J Thyroid Res 2011; 2011: 384213.
6. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-79.
7. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-90.
8. Pieczyńska B, Wojtylak S, Zawrocki A, Biernat W. Analysis of PTEN, estrogen receptor α and progesterone receptor expression in endometrial hyperplasia using tissue microarray. Pol J Pathol 2011; 62: 133-8.
9. Waniczek D, Snietura M, Pigłowski W, Rdes J, Kopeć A, Młynarczyk-Liszka J, Rudzki M, Hudyka K, Arendt J, Lange D. Analysis of PTEN expression in large intestine polyps and its relation to the recognized histopathological and clinical risk factors for cancer development in this location. Contemp Oncol (Pozn) 2012; 16: 310-5.
10. Waniczek D, ͆nietura M, Młynarczyk-Liszka J, Pigłowski W, Kopeć A, Lange D, Rudzki M, Arendt J. PTEN expression profiles in colorectal adenocarcinoma and its precancerous lesions. Pol J Pathol 2013; 64: 15-20.
11. Souza EC, Ferreira AC, Carvalho DP. The mTOR protein as a target in thyroid cancer. Expert Opin Ther Targets 2011; 15: 1099-112.
12. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88: 2745-52.
13. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003; 120: 71.
14. Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, Nortier JW, Smit JW. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012; 23: 10-8.
15. Gut P, Matysiak-Grzes̈ M, Fischbach J, Klimowicz A, Gryczyńska M, Ruchała M. Lack of TSH stimulation in patients with differentiated thyroid cancer - possible causes. Contemp Oncol (Pozn) 2012; 16: 273-5.
16. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007; 13: 1161-70.
17. Santarpia L, Myers JN, Sherman SI, et al. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 2010; 116: 2974-83.
18. Kemmochi S, Fujimoto H, Woo GH, et al. Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine. J Cancer Res Clin Oncol 2011; 137: 723-32.
19. Sozopoulos E, Litsiou H, Voutsinas G, et al. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocr Pathol 2010; 21: 90-100.
20. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008; 93: 3106-16.
21. Wang Y, Hou P, Yu H, et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 2007; 92: 2387-90.
22. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997; 57: 4710-3.
23. Bruni P, Boccia A, Baldassarre G, et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000; 19: 3146-55.
24. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 2007; 204: 764-55.
25. Yeager N, Brewer C, Cai KQ, Xu XX, Di Cristofano A. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res 2008; 68: 444-9.
26. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
27. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-63.
28. Kim CS, Vasko VV, Kato Y, et al. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 2005; 146: 4456-63.
29. Vasko V, Saji M, Hardy E, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004; 41: 161-70.
30. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-9.
31. Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21: 3226-35.
32. Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008; 68: 618-34.
33. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69: 4885-93.
34. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-62.
35. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010; 321: 86-93.
36. Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008; 93: 611-8.
37. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 2009; 69: 3689-94.
38. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008; 113: 48-56.
39. Kaczka K, Fendler W, Borowiec M, Młynarski W, Celnik A, Pomorski L. Lymph node metastases in papillary thyroid cancer detected by quantitative real-time polymerase chain reaction for thyroglobulin and cytokeratine-19. Pol J Pathol 2013; 64: 90-5.
40. Lan Shi, Haiping Song, Huiping Zhu, Dapeng Li, Ning Zhang. Pattern, predictors and recurrence of cervical lymph node metastases in papillary thyroid cancer. Contemp Oncol (Pozn) 2013; 17: 504-9.
41. Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009; 69: 7311-9.